Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Danaher (DHR) is a Top-Ranked Momentum Stock: Should You Buy?

AMERSHAM, United Kingdom, July 27, 2021 /PRNewswire/ -- An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments.

Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

BREA, Calif., July 26, 2021 /PRNewswire/ -- Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers.

Beckman Coulter to Distribute BNP Cardiac Assay to Customers

Danaher's (DHR) Q2 results reflect strength in segmental businesses, the impact of pandemic-led tailwinds and improved margins. Projection for core sales growth, including Cytiva, increases for 2021.

Danaher (DHR) Beats on Q2 Earnings, Ups 2021 Core Sales View

Danaher Corporation (DHR) CEO Rainer Blair on Q2 2021 Results - Earnings Call Transcript

Danaher (DHR) delivered earnings and revenue surprises of 20.59% and 7.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Tops Q2 Earnings and Revenue Estimates

Danaher Corporation (NYSE: DHR) logged a higher profit for the second quarter as its sales grew. Adjusted EPS increased 71% Y/Y to $2.46, surpassing the estimate of $2.05.

Danaher Posts Higher Profits, Margins On Increased Sales

Danaher sales top analyst estimates

WASHINGTON, July 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted.

Danaher Reports Second Quarter 2021 Results

The stock price of Danaher, a conglomerate with products in environmental, life sciences, and diagnostics fields, has seen a 10% rise over the last twenty-one trading days, while it is up 47% over the last year, driven by positive developments for the company.

Here's Why Danaher Stock May Continue To Rise In The Near Term

Danaher (NYSE:DHR) unveils its next round of earnings this Thursday, July 22. Get prepared with Benzinga's ultimate preview for Danaher's Q2 earnings.

A Preview Of Danaher's Earnings

Danaher is one of those incredible long-term value creators, driven by its superior capital allocation skills and sound business positioning.

Danaher: Simply Impressive

Abbott Labs

Domino's Pizza

Pool

Whirlpool

These companies have earnings surprise track records and charts to envy.

5 Hottest Earnings Charts This Week

Invesco S&P Global Water Index ETF

First Trust Water ETF

Invesco Water Resources ETF

Roper Technologies

Waters

Water sustainability is a growing concern for many investors

Here's Why You Should Invest in Water ETFs

Federal Signal

FSS vs. DHR: Which Stock Is the Better Value Option?

FSS vs. DHR: Which Stock Should Value Investors Buy Now?

Danaher (DHR) Q2 performance is likely to have gained from the pandemic-induced demand for products, focus on innovation and synergistic gains from acquired assets.

Danaher (DHR) to Post Q2 Earnings: What's in the Offing?

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Danaher (DHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Curaleaf Holdings, Inc.

GlaxoSmithKline

IQVIA Hlds

Intuitive Surgical

Jazz Pharmaceuticals

LHC Group

Moderna

Invesco S&P 500 Equal Weight Health Care ETF

UnitedHealth Group

Vertex Pharmaceuticals

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyond.

11 Best Healthcare Stocks for the Rest of 2021

WASHINGTON, June 22, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2021 on Thursday, July 22, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules Second Quarter 2021 Earnings Conference Call

Accenture Plc

Thermo Fisher Scientific

When the operating income margin continues to expand, it means that the company is becoming more efficient in generating profits from its operations.

A Trio of Stocks With a Record of Operating Income Margin Growth

Crane Company

Carlisle Companies

Griffon

5 Stocks to Ride High in Booming Diversified Operations Industry

Caterpillar

Deere & Company

Alphabet

Philip Morris

Target

Taiwan Semiconductor Manufacturing

During this unsettled time, there are some great deals on great blue-chip stocks. Here are eight to consider buying now.

8 Blue-Chip Stocks to Buy to Fortify Your Portfolio

Danaher (DHR) to gain from the Aldevron acquisition as it will increase growth opportunities in the genomic medicine field. The acquired assets will be integrated with Danaher's Life Sciences segment.

Danaher's (DHR) Aldevron Buyout to Aid Genomic Medicine

Danaher (DHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Danaher (DHR) Moves 5% Higher: Will This Strength Last?

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #beextraordinary--SCIEX OS introduces new software with OneOmics suite in SCIEX Cloud and Molecule Profiler app.

News for Danaher Stock (DHR)